News Alkermes may separate oncology business, says CEO Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.
News Pfizer’s CNS exit takes the form of a biotech spinout Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of spinout biotech Cerevel Therapeutics.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends